All High-Throughput Screening (HTS) articles – Page 4
-
NewsLive-cell liquid biopsy study aims to transform cancer treatment
Vortex Liquid Biopsy Solutions has launched a new clinical study with The Doctors Laboratory to assess how its live-cell liquid biopsy technology could change cancer monitoring and treatment.
-
NewsBlocking the P2X4 receptor: a potential pathway to new therapies
Researchers have discovered how to inhibit the P2X4 receptor, a key protein linked to chronic pain, inflammation and certain cancers.
-
ArticleLogic-gated DARPins show targeted T-cell activation in tumours
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
-
NewsNew organ-on-a-chip captures ageing immune responses to cancer vaccines
Scientists have developed an organ-on-a-chip platform that replicates age-related immune decline, offering a long-missing tool for testing cancer vaccines in older adults.
-
ArticleRNA that knows where to go: the rise of targeted delivery
What if RNA medicines could be guided directly to tumours, sparing healthy tissue and reducing side effects? Advances in targeted delivery are bringing that vision closer to reality.
-
NewsFibulin-5 linked to early detection of liver fibrosis
Researchers in Japan have identified a promising blood-based marker that could enable faster, simpler and more accurate detection of liver fibrosis.
-
NewsBits2Bonds: AI system accelerates discovery of RNA delivery polymers
Researchers at LMU Munich have developed Bits2Bonds, the first platform to fuse molecular simulations with machine learning – accelerating the discovery of polymer carriers for therapeutic RNA.
-
NewsAutomated lung organoids to speed up new drug development
Scientists have developed an automated method to grow lung organoids, with the hope of speeding up drug testing, reducing reliance on animal models and helping to develop new personalised treatments.
-
ArticleThe partnership changing the pace of radiopharmaceutical development
A new collaboration between Crown Bioscience and Medicines Discovery Catapult is bringing advanced tumour models together with world-class imaging and radiochemistry to accelerate the development of next-generation radiopharmaceuticals.
-
NewsRomidepsin drug combo proves effective against resistant childhood cancer
Australian researchers have identified a promising drug combination that can bypass treatment resistance in relapsed neuroblastoma, offering hope in the fight against one of the deadliest childhood cancers.
-
ArticleRedesigning paclitaxel: expanding the therapeutic window through oral delivery
The potent chemotherapy drug paclitaxel is widely employed for various cancers despite toxicity and efficacy challenges. Maite Agüeros reveals how novel nanoparticle technology has enabled oral delivery of the drug – showing promising signs of improved tolerability and treatment success.
-
NewsKidney fibrosis linked to overactive Hippo signalling pathway
Scientists have used human stem cell–derived kidney organoids to uncover how abnormal Hippo signalling drives scarring in nephronophthisis, a rare genetic kidney disease.
-
ArticleThe mother of invention: from steam engines to AI-designed drugs
Every great leap in history started with a single, urgent need. Now AI is emerging as the next great engine of invention, transforming the future of medicine faster than ever imagined.
-
NewsKinase inhibitors shown to accelerate protein breakdown
A new study has revealed that many kinase inhibitors – key drugs used in cancer and other diseases – also trigger the accelerated degradation of their target proteins, which could inform future therapies.
-
NewsTargeting p300 may boost immunotherapy in kidney cancer
Researchers have discovered how renal medullary carcinoma cells evade immunotherapy by mimicking immune cells, driving rapid tumour progression.
-
ArticleMapping the genome in 3D to reveal new drug targets
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
-
OpinionMaking science run at the speed of thought: the reality of AI in drug discovery – Part 2
Can automation and AI finally make science run at the speed of thought? Eric Ma shares how disciplined systems, not new models, will drive the next wave of discovery.
-
ArticleFast, scalable free energy prediction with nonequilibrium switching
Nonequilibrium switching (NES) offers a faster, more scalable way to predict how strongly drugs bind to their targets. By replacing slow equilibrium simulations with rapid, parallel transitions, NES delivers accurate free energy predictions at speed.
-
NewsOral arginine reduces harmful amyloid in Alzheimer’s models
A naturally occurring amino acid commonly found in supplements has reduced harmful amyloid build-up and eased symptoms in animal models of Alzheimer’s disease.
-
ArticleMapping lipid pockets to drug the undruggable proteome
Tasca Therapeutics is using chemical proteomics to map lipid-binding pockets on proteins. By targeting auto-palmitoylation, the company aims to turn previously undruggable cancer drivers into viable therapeutic targets.